EICHOR
● Active Not Recruiting
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Condition: Leukemia, Lymphocytic, Chronic, B-Cell · Small Lymphocytic Lymphoma · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (74)
| The Oncology Institute Clinical Research | Cerritos, California, United States | — |
| Cancer and Blood Specialty Clinic | Los Alamitos, California, United States | — |
| SLO Oncology and Hematology Health Center | San Luis Obispo, California, United States | — |
| Providence Medical Foundation | Santa Rosa, California, United States | — |
| PIH Health Hospital | Whittier, California, United States | — |
| Grand Valley Oncology | Grand Junction, Colorado, United States | — |
| Mount Sinai Medical Center Campus | Miami Beach, Florida, United States | — |
| The Oncology Institute | North Miami Beach, Florida, United States | — |
| Mid Florida Hematology Oncology | Orange, Florida, United States | — |
| Boise VA Medical Center | Boise, Idaho, United States | — |
| Hope and Healing Cancer Services | Hinsdale, Illinois, United States | — |
| Springfield Clinic | Springfield, Illinois, United States | — |
+ 62 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.